ArticleDermatology and therapy2026
D-CARE (Delgocitinib-Chronic hAnd Eczema Response Evaluation): A Retrospective, Multicenter, Real-World Study of Patients with Chronic Hand Eczema (CHE) Treated with Delgocitinib 2% Cream-Temporal Analysis of Symptom and Clinical Sign Response.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic hand eczema (CHE) is a frequent and often refractory inflammatory skin disease with a substantial impact on quality of life. Delgocitinib 2% cream has demonstrated efficacy in phase 3 trials, but real-world evidence remains limited. This study evaluated its effectiveness and the temporal dynamics of clinical and symptomatic response in patients with CHE.
methodsThis multicenter, retrospective observational study included 58 adults with CHE treated with delgocitinib 2% cream and followed for 16 weeks. Clinical severity and patient-reported outcomes were assessed at baseline, week 4, and week 16. Changes in the Hand Eczema Severity Index (HECSI), global assessment scores, pruritus, pain, and quality of life were analyzed, together with the evolution of individual HECSI components across anatomical regions.
resultsAll clinical and patient-reported outcomes improved significantly during follow-up (all p < 0.001). Mean HECSI decreased from 71.5 ± 29.2 at baseline to 19.5 ± 15.1 at week 4 and 6.8 ± 8.9 at week 16. Pruritus and pain both showed marked reductions during follow-up. At week 4, mean vesicle and edema scores were 0.0-0.1 across anatomical regions, while desquamation remained 1.0 ± 1.1 at the fingertips and fingers; at week 16, fissure scores were 0.2 and 0.3 and desquamation scores were 0.4 and 0.3 at the fingertips and fingers, respectively. Quality of life also improved substantially. Two patients (3.4%) experienced adverse events leading to treatment discontinuation.
conclusionsDelgocitinib 2% cream showed rapid and clinically meaningful real-world effectiveness in CHE. Inflammatory signs improved earlier than chronic structural features such as fissures and desquamation. These differential response kinetics may help clinicians interpret early partial responses and counsel patients regarding expected treatment timelines.
Indexed as
Identifiers
42825994What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.